About CCDx
Cancer diagnostics reimagined.
CCDx is pioneering the use of intact whole circulating tumor cells (CTCs) in liquid biopsy. Our proprietary CellSight™ platform enables comprehensive tumor profiling—without a surgical biopsy—so patients can get answers faster, and clinicians can make better-informed treatment decisions.
We’re a team of scientists, clinicians, and innovators on a mission to modernize cancer diagnostics with precision, speed, and accessibility.
Mission & Vision
Mission: To bring clarity to every cancer journey through innovative, noninvasive diagnostics that enable faster, smarter treatment decisions.
Vision: A world where every cancer patient has access to deep molecular insights, without waiting, without surgery, without compromise.
We are molecular biologists, bioinformaticians, clinical researchers, and commercial leaders united by one goal:
Change how cancer is diagnosed and treated.
Our Team
Tifiny McDonald
Chief Executive & Financial Officer
Chief Financial Advisor, Capital Management Group; Chief Financial Officer, Boundary Stone Partners; Chief Financial & Operations Officer, Trident Management Services.
Cheri Copie
Chief Operating & Compliance Officer
Certified in Healthcare Compliance for 23+ years. Active, multistate R.N. license; Compliance Officer for NeoGenomics Laboratories, and Compliance Officer for another publicly-traded laboratory.
Steve Brodie
Chief Scientific Officer
Fellow American Board of Medical Genetics and Genomics (FACMGG); President Pharma Services, Senior VP of Operations & Global Laboratory Director, NeoGenomics Laboratories; Director of Molecular Genetics and Cytogenetics; Quest Diagnostics Academic Positions, UCLA, UNM, NIH (NIDDK)
Kyle Dunn
Senior Growth & Informatics Advisor
Founder and Principal of Hyperdrive Bio. Former Chief Revenue Officer at Aster Insights and Vice President of Sales and Commercial Strategy at NeoGenomics, where he built the oncology data and real-world data business and launched its informatics and precision medicine division.